Find and compare companies providing Drug Substance (CDMO/CRO) services for:
Small Molecule APIs

A small molecule active pharmaceutical ingredient CDMO develops and manufactures the chemical drug substance used in medicines. Typical work includes route scouting, process development, scale-up, GMP synthesis, and analytical testing.

Small molecule CDMO outsourcing focuses on making the active pharmaceutical ingredient, not tablets or capsules. Drug product manufacturing starts after the API is produced and released.

Services typically include process development, scale-up, GMP manufacturing, impurity profiling, and documentation for regulatory filings. Some partners also provide tech transfer and validation support.

Include the target molecule or route, required batch sizes, potency or containment limits, target markets, and expected timelines. Add analytical methods, impurity concerns, and any solvent or catalyst constraints.

Many do, but potency handling varies by facility. Ask for OEB limits, containment validation, and examples at similar scales.

Confirm the specific facility has recent inspections aligned to your target markets and that the equipment train matches your chemistry. Review change control, deviation handling, and batch record practices.

Scale-up usually moves from kilo lab to pilot and commercial campaigns. Each step verifies critical parameters like temperature control, mixing, and impurity formation before GMP batches.

Yes. Provide process descriptions, analytical methods, and critical quality attributes to reduce transfer risk. A clear comparability plan is essential when switching sites.

Analytical development and QC are critical for impurity control and release testing. In-house methods generally speed up investigations and reduce outsourcing delays.

Timelines depend on route maturity, raw material availability, and capacity. Mature processes move faster, while new routes may require additional development cycles.

Most provide documentation for drug master files and regulatory submissions. Confirm the scope of CMC writing and data package expectations early.

Common pitfalls include underestimating impurity risks, unclear specifications, and limited raw material sourcing plans. Early alignment on quality targets and supply continuity prevents delays.

Yes, many CDMOs supply intermediates or key starting materials in addition to the final API. Ask which steps are in-scope and how traceability is maintained.

Use the filters for region, containment, stage, and services to remove obvious mismatches. Then compare experience with similar chemistry and scale.